RALLYBIO CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
RALLYBIO CORPORATION (RLYB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.60 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-26
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $3.60, a 32.84% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $5.36, a 264.63% increase year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.47, a 70.54% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.99, a 54.47% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $4.93, a 50.65% decline from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $9.99, a 8.00% increase from fiscal 2021.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $9.25.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.60 S-4/A · filed 2026-08-26 | ||||||
| 2026-03-31 | $3.60 S-4 · filed 2026-07-15 | ||||||
| 2025-12-31 | $4.92 S-4/A · filed 2026-08-26 | ||||||
| 2025-09-30 | $0.62 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | $4.96 S-4/A · filed 2026-08-26 | $0.62 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | $5.36 S-4 · filed 2026-07-15 | $0.67 10-Q · filed 2025-05-08 | |||||
| 2024-12-31 | $11.78 S-4/A · filed 2026-08-26 | $1.47 10-K · filed 2025-03-13 | |||||
| 2024-09-30 | $1.47 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | $1.47 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | $1.47 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | $4.93 10-K · filed 2025-03-13 | ||||||
| 2023-09-30 | $4.93 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | $4.93 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | $4.99 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $9.99 10-K · filed 2024-03-12 | ||||||
| 2022-09-30 | $9.99 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | $10.17 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $10.96 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | $9.25 10-K · filed 2023-03-06 | ||||||
| 2021-09-30 | $9.40 10-Q · filed 2022-11-07 | ||||||
| 2018-12-31 | $0.15 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |